These innovative agents represent a significant progression in the management of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in reducing blood glucose https://gretawhok369048.livebloggs.com/45791726/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide